Rothschild Capital Partners LLC maintained its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX) during the second quarter, according to its most recent disclosure with the SEC. The firm owned 3,222 shares of the medical research company’s stock at the end of the second quarter. Rothschild Capital Partners LLC’s holdings in Quest Diagnostics were worth $358,000 at the end of the most recent quarter.
Several other hedge funds have also made changes to their positions in DGX. YorkBridge Wealth Partners LLC boosted its position in shares of Quest Diagnostics by 1.5% in the first quarter. YorkBridge Wealth Partners LLC now owns 1,188 shares of the medical research company’s stock worth $127,000 after buying an additional 18 shares during the last quarter. Parallel Advisors LLC boosted its position in shares of Quest Diagnostics by 16.1% in the first quarter. Parallel Advisors LLC now owns 1,279 shares of the medical research company’s stock worth $137,000 after buying an additional 177 shares during the last quarter. Advisors Capital Management LLC purchased a new position in shares of Quest Diagnostics during the first quarter worth about $164,000. Trust Co. of Vermont boosted its position in shares of Quest Diagnostics by 8.5% in the first quarter. Trust Co. of Vermont now owns 1,859 shares of the medical research company’s stock worth $182,000 after buying an additional 145 shares during the last quarter. Finally, Perkins Capital Management Inc. purchased a new position in shares of Quest Diagnostics during the first quarter worth about $201,000. Hedge funds and other institutional investors own 90.06% of the company’s stock.
Quest Diagnostics Incorporated (NYSE:DGX) traded down 0.47% during midday trading on Friday, hitting $104.87. 779,220 shares of the stock traded hands. Quest Diagnostics Incorporated has a 12 month low of $79.12 and a 12 month high of $112.96. The company has a 50-day moving average of $108.23 and a 200-day moving average of $103.54. The stock has a market cap of $14.30 billion, a PE ratio of 21.13 and a beta of 0.69.
Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings results on Tuesday, July 25th. The medical research company reported $1.55 earnings per share for the quarter, beating the consensus estimate of $1.42 by $0.13. The company had revenue of $1.94 billion during the quarter, compared to analysts’ expectations of $1.94 billion. Quest Diagnostics had a return on equity of 15.66% and a net margin of 9.28%. Quest Diagnostics’s quarterly revenue was up 1.9% on a year-over-year basis. During the same period last year, the business earned $1.34 earnings per share. On average, equities research analysts anticipate that Quest Diagnostics Incorporated will post $5.69 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 18th. Investors of record on Tuesday, October 3rd will be given a dividend of $0.45 per share. This represents a $1.80 annualized dividend and a yield of 1.72%. The ex-dividend date is Monday, October 2nd. Quest Diagnostics’s dividend payout ratio is currently 36.29%.
A number of equities analysts recently issued reports on DGX shares. Mizuho upped their price target on shares of Quest Diagnostics from $110.00 to $115.00 and gave the stock a “buy” rating in a research note on Wednesday, April 26th. Canaccord Genuity upped their price target on shares of Quest Diagnostics from $102.00 to $115.00 and gave the stock a “buy” rating in a research note on Tuesday, April 25th. UBS AG reissued a “buy” rating and issued a $115.00 target price (up previously from $102.00) on shares of Quest Diagnostics in a research report on Tuesday, April 25th. Deutsche Bank AG reissued a “buy” rating and issued a $115.00 target price (up previously from $108.00) on shares of Quest Diagnostics in a research report on Sunday, April 23rd. Finally, Zacks Investment Research raised Quest Diagnostics from a “hold” rating to a “buy” rating and set a $119.00 target price for the company in a research report on Tuesday, May 23rd. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Quest Diagnostics has a consensus rating of “Hold” and an average price target of $109.62.
In related news, SVP Catherine T. Doherty sold 59,762 shares of Quest Diagnostics stock in a transaction that occurred on Monday, June 19th. The stock was sold at an average price of $107.55, for a total transaction of $6,427,403.10. Following the completion of the transaction, the senior vice president now directly owns 78,582 shares in the company, valued at $8,451,494.10. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jeffrey M. Leiden sold 296 shares of Quest Diagnostics stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $106.66, for a total value of $31,571.36. Following the transaction, the director now owns 6,000 shares of the company’s stock, valued at $639,960. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 61,362 shares of company stock valued at $6,600,758. 1.50% of the stock is owned by company insiders.
About Quest Diagnostics
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).
Receive News & Ratings for Quest Diagnostics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.